By indication / Hepatobiliary and pancreatic cancer
Hepatobiliary and pancreatic cancer
7 imaging agents and 11 therapeutic agents reported for this indication. Stage reflects how far each has been taken, not what is available in any given country.
Imaging
| Agent | Isotope | Stage | Syntheses |
|---|---|---|---|
| [18F]AlF-NOTA-FAPI-04 | F-18 | — | 7 |
| [68Ga]Ga-FAP-2286 paired with [177Lu]Lu-FAP-2286 | Ga-68 | — | 7 |
| [18F]fluoro-2-deoxy-D-galactose | F-18 | — | 2 |
| [18F]fluoroacetate | F-18 | — | 2 |
| [11C]SSI-4 | C-11 | preclinical | 1 |
| [18F]L-Glutamic | F-18 | investigational | |
| [68Ga]Ga-FAPI-74 | Ga-68 | — |
Therapy
| Agent | Isotope | Stage | Syntheses |
|---|---|---|---|
| [90Y]Y-microsphere | Y-90 | approved | 11 |
| [177Lu]Lu-FAP-2286 paired with [68Ga]Ga-FAP-2286 | Lu-177 | first-in-human | 4 |
| [166Ho]Ho-166-PLLA | Ho-166 | — | 3 |
| [177Lu]Lu-Gemini | Lu-177 | — | 2 |
| [90Y]Y-90-ITGA6B4 | Y-90 | — | 2 |
| [212Pb]Pb-DO3A-PEG7-Tz | Pb-212 | preclinical study | 2 |
| [177Lu]Lu-DOTA-2P(FAPI)2 | Lu-177 | preclinical | 1 |
| [131I]I-131-SFMS | I-131 | — | 1 |
| [177Lu]Lu-DTPA-PODSAJICAP-5B1 | Lu-177 | Reported once | 1 |
| [90Y]Y-L4-Lipo/ | Y-90 | Reported once | 1 |
| [177Lu]Lu-DOTA-FD2 paired with [68Ga]DOTA-FD2 | Lu-177 | Reported once | 1 |
Have a question?Reagents, modules, introductions to manufacturers or to specialists in your region — tell us what you need.
Get in touch